|
|
Sold Out
Book Categories |
| Acceptance Sampling | 1 | |
| Active Control Trials | 9 | |
| Adaptive Survival Trials | 16 | |
| Adjustment for Covariates | 18 | |
| Adverse Event Reporting | 22 | |
| Ames Test | 28 | |
| Analysis of Heritability | 36 | |
| Analysis of Variance | 42 | |
| Assay Development | 55 | |
| Assay Validation | 63 | |
| Bayesian Statistics | 72 | |
| Bioassay | 80 | |
| Bioavailability and Bioequivalence | 83 | |
| Biologics | 89 | |
| Biopharmaceutics | 100 | |
| Blinding | 121 | |
| Bootstrap, The | 127 | |
| Bracketing Design | 133 | |
| Bridging Studies | 134 | |
| Calibration | 139 | |
| Canadian Health Products and Food Branch (HPFB) and Therapeutic Products Directorate (TPD) | 147 | |
| Cancer Trials | 152 | |
| Carcinogenicity Studies of Pharmaceuticals | 160 | |
| Carry-Foward Analysis | 175 | |
| Clinical Data Management | 181 | |
| Clinical Endpoint | 189 | |
| Clinical Pharmacology | 193 | |
| Clinical Trial Process | 196 | |
| Clinical Trial Simulation | 200 | |
| Clinical Trials | 202 | |
| Combination Drug Clinical Trial | 210 | |
| Comparing Variabilities in Clinical Research | 214 | |
| Confidence Interval and Hypothesis Testing | 231 | |
| Confounding and Interaction | 235 | |
| Content Uniformity | 241 | |
| Contract Research Organization (CRO) | 244 | |
| Cost-Effectiveness Analysis | 249 | |
| Crossover Design | 255 | |
| Cutoff Designs | 263 | |
| Data Mining and Biopharmaceutical Research | 270 | |
| Data Monitoring Committees (DMC) | 277 | |
| Diagnostic Imaging | 288 | |
| Dose Proportionality | 295 | |
| Dose Response Analysis in Clinical Trials | 298 | |
| Dose Response Study Design | 304 | |
| Dropout | 311 | |
| Drug Development | 317 | |
| Enrichment Design | 324 | |
| Equivalence Trials | 327 | |
| Ethnic Factors | 333 | |
| Expiration Dating Period | 336 | |
| Exploratory Factor Analysis | 343 | |
| Extra Variation Models | 349 | |
| Factorial Designs | 364 | |
| Food and Drug Administration | 379 | |
| Generalizability Probability in Clinical Research | 386 | |
| Generalized Estimating Equation | 390 | |
| Global Database and System | 397 | |
| Good Clinical Practice | 403 | |
| Good Programming Practice | 410 | |
| Good Statistics Practice | 417 | |
| Group Sequential Methods | 423 | |
| Hypothesis Testing | 433 | |
| Imputation in Clinical Research | 437 | |
| Imputation with Item Nonrespondents | 443 | |
| In Vitro Bioequivalence Testing | 449 | |
| In Vitro Dissolution Profile Comparison | 456 | |
| In Vitro Micronucleus Test | 463 | |
| Individual Bioequivalence | 468 | |
| Instrument Development and Validation | 476 | |
| Integrated Summary Report | 486 | |
| Intention-to-Treat Analyses (ITT) | 490 | |
| Interactive Voice Randomization System (IVRS) | 494 | |
| Interim Analysis | 502 | |
| International Conference on Harmonization (ICH) | 508 | |
| Investigating Quality-of-Life in Clinical Trials | 512 | |
| Kaplan-Meier Estimator | 518 | |
| Laboratory Analyses | 524 | |
| Lilly Reference Ranges | 532 | |
| Logistic Regression | 548 | |
| Maximum Tolerable Dose for Cancer Chemotherapy | 554 | |
| Measuring Agreement | 561 | |
| MedDRA and Its Impact on Pharmaceutical Development | 568 | |
| Medical Devices | 574 | |
| Meta-Analysis of Therapeutic Trials | 586 | |
| Microarray Gene Expression | 599 | |
| Minimization Procedure | 614 | |
| Minimum Effective Dose | 619 | |
| Ministry of Health, Labour and Welfare and Pharmaceutical Administration in Japan | 622 | |
| Mixed Effects Models | 630 | |
| Multicenter Trials | 635 | |
| Multinational Clinical Trial | 639 | |
| Multiple Comparisons | 647 | |
| Multiple-Dose Bioequivalence Studies | 652 | |
| Multiple Endpoints | 656 | |
| Multiplicity in Clinical Trials | 666 | |
| Noninferiority Analysis in Active Controlled Clinical Trials | 674 | |
| Odds Ratio | 678 | |
| P-Values | 685 | |
| P-Values, Evidence and Multiplicity Considerations for Controlled Clinical Trials | 696 | |
| Parallel Design | 707 | |
| Patient Compliance | 712 | |
| Pharmacodynamic Issues | 718 | |
| Pharmacodynamics with Covariates | 727 | |
| Pharmacodynamics with No Covariates | 740 | |
| Pharmacoeconomics | 749 | |
| Placebo Effect | 764 | |
| Population Bioequivalence | 769 | |
| Postmarketing Adverse Drug Event Signaling | 776 | |
| Postmarketing Surveillance | 790 | |
| Power | 798 | |
| Process Validation | 800 | |
| Proportional Hazards Regression Model | 816 | |
| Protocol Development | 824 | |
| Randomization | 828 | |
| Release Targets | 833 | |
| Reproducibility Probability in Clinical Research | 838 | |
| Reproductive/Developmental Studies | 850 | |
| Response Surface Methodology | 858 | |
| Robust Analysis for Crossover Design | 870 | |
| ROC Curve | 884 | |
| Sample Size Calculation for Survival Data | 892 | |
| Sample Size Determination | 899 | |
| Sample Size Re-estimation Based on Observed Treatment Difference | 915 | |
| Screening Design | 920 | |
| Selection of Control in Clinical Trials | 921 | |
| Specifications | 927 | |
| Stability Analysis for Frozen Drug Products | 929 | |
| Stability Matrix Designs | 934 | |
| Statistical Principles for Clinical Trials | 940 | |
| Statistical Process Control | 945 | |
| Statistical Significance | 954 | |
| Subgroup Analysis | 959 | |
| Surrogate Endpoint | 967 | |
| Survival Analysis | 972 | |
| Therapeutic Equivalence | 977 | |
| Titration Design | 983 | |
| Toxicological Studies | 988 | |
| USP Tests | 1003 | |
| Vaccine Clinical Trials | 1005 | |
| Validity of LOCF | 1023 |
| Price | Condition | Delivery | Seller | Action |
| $873.60 | Digital |
| WonderClub |
Makis Kalidis
reviewed Encyclopedia of Biopharmaceutical Statistics, Second Edition on June 03, 2020
Encyclopedia of Biopharmaceutical Statistics
The book opens with the mass poisoning of thousands of people in Bangladesh by drinking water contaminated with arsenic. This book has a very important current environmental message for all of us because environmental arsenic is not just a problem facing Bangladesh. There is a USGS map on page 161 showing the states in the U.S. where acquifers used for drinking water contain dangerously high levels of arsenic. As a cancer patient, I have often wondered why I keep meeting people who are being treated for cancer but are in none of the high-risk groups. I was surprised to read in this book that years of exposure to water contaminated with non-lethal levels of arsenic causes lung cancer. Unfortunately, this surprising information is floating around in a hodge-podge of history and unrelated anecdotes.
I would have assumed that a major publishing company like Macmillan still employed editors in 2005 but, apparently, I was wrong. The author is obviously extremely knowledgeable, and the separate topics he addresses are all interesting but the book is totally disjointed.
I imagine that the author wrote a long academic article addressing the arsenic contaminated well water in Bangladesh, a medium length exposé on the history and ethics of William Morris & Company. Someone remarked "You have almost enough material for a book." The author tossed in a short popular article on the worldwide problem of environmental arsenic, and several short sensational anecdotes about murders committed using arsenic and mailed the separate articles to Macmillan. His publisher dropped the articles on the floor, told an intern to put them back in order and then published them.
Login|Complaints|Blog|Games|Digital Media|Souls|Obituary|Contact Us|FAQ
CAN'T FIND WHAT YOU'RE LOOKING FOR? CLICK HERE!!! X
You must be logged in to add to WishlistX
This item is in your Wish List
X
This item is in your Collection
Encyclopedia of Biopharmaceutical Statistics, Second Edition
X
This Item is in Your Inventory
Encyclopedia of Biopharmaceutical Statistics, Second Edition
X
You must be logged in to review the productsX
X
X
Add Encyclopedia of Biopharmaceutical Statistics, Second Edition, The only encyclopedia that specifically focuses on biopharmaceutical statistics, the 3rd Edition provides a well-balanced summary of current regulatory requirements, along with a comprehensive and unified presentation of designs and analyses used at diffe, Encyclopedia of Biopharmaceutical Statistics, Second Edition to the inventory that you are selling on WonderClubX
X
Add Encyclopedia of Biopharmaceutical Statistics, Second Edition, The only encyclopedia that specifically focuses on biopharmaceutical statistics, the 3rd Edition provides a well-balanced summary of current regulatory requirements, along with a comprehensive and unified presentation of designs and analyses used at diffe, Encyclopedia of Biopharmaceutical Statistics, Second Edition to your collection on WonderClub |